EP0215925A4 - Supplemental calcium addition unit. - Google Patents
Supplemental calcium addition unit.Info
- Publication number
- EP0215925A4 EP0215925A4 EP19860902230 EP86902230A EP0215925A4 EP 0215925 A4 EP0215925 A4 EP 0215925A4 EP 19860902230 EP19860902230 EP 19860902230 EP 86902230 A EP86902230 A EP 86902230A EP 0215925 A4 EP0215925 A4 EP 0215925A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- solution
- calcium
- ampule
- amino acid
- intravenously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Definitions
- Amino acid in solutions suitable for injection are used with critically ill patients to provide nu- trition.
- the injectable amino acid solutions are sold without certain electrolytes which may be needed by a patient. In that circumstance, it becomes desirable for the doctor to add appropriate electrolytes to the container of amino acid solution immediately prior to intravenous administration to the patient.
- electrolytes often added are phos ⁇ phate and calcium, as well as other physiologica] elec- trolytes.
- Amino acid solutions have been provided in glass bottles, where they may have a relatively low pH.
- small amounts of phosphate and calcium may be added to the amino acid solution without the risk of forming a precipitate, because the pH of amino acid solutions currently sold in bottles is sufficiently low to prevent the precipitation of, for example, dibasic calcium phosphate.
- a supplemental calcium addition unit for administering dissolved calcium to a container of phosphate-containing intravenous amino acid solution.
- the unit comprises an ampule, plus means carried on the ampule for facilitatingsubstantially aseptic fluid flow connection with the interior of said container.
- This may constitute any of various conventional means for transferring an ampule of material in aseptic manner to a larger container.
- the ampule may carry a needle-pierceable latex wall, which may be penetratedin conventional manner with a needle and syringe.
- the ampule contains a solution of intravenously metabolizable calcium compound at a pH of 2 to 5.5. Accordingly, sufficient acidity may be provided by the contents of the ampule, so that when the calcium c ⁇ pound is added to phosphate-containing intravenous amino acid solution, no precipitation takes place.
- the solution inside the ampule may typically con- tain from 5 to 25 weight percent of calcium gluconate, a known metabolizable calcium compound, plus sufficient gluconic acid to provide to the solution a preferredpH of 3 to 4.
- the solution may also contain from 4 to 6 mg. of calcium d-saccharate per ml. of solution whichis present, as a precipitation inhibitor as well as a source of added calcium and as a stabilizer.
- metabolizable calcium which may be used in the supplemental calcium addition unit include calcium chloride, calcium acetate, calcium lactate, cal ⁇ cium ascorbate, or calcium succinate.
- acids besides gluconic acid may also be used to provide a pH within the desired range, for example acetic acid, hydrochloric acid, ascorbic acid, lactic ac- id, succinic acid, or any other desired acid which would be suitable for use in an injectable solution at the appropriate pH.
- the solution may be prepared by adding the desired amount of calcium gluconate (preferably 10 to 20 percent by weight) to rapidly boiling water for in ⁇ jection, which may be present in about 80 percent of the total volume of solution required, with constantstirring.
- the desired amount of calcium gluconate preferably 10 to 20 percent by weight
- the desired amount of calcium gluconate preferably 10 to 20 percent by weight
- the desired amount of calcium gluconate preferably 10 to 20 percent by weight
- the desired amount of calcium gluconate preferably 10 to 20 percent by weight
- rapidly boiling water for in ⁇ jection which may be present in about 80 percent of the total volume of solution required, with constantstirring.
- calcium d-saccharate may be added. Twice this amount of calcium d-saccharate may be added for a 15 percent solution of calcium gluconate.
- the solution becomes clear after 2 or 3 minutes of continuous boiling.
- the solution is then allowed to cool to room temperature.
- 50 percent gluconic acid may be added incrementally until the pH of the solution is, preferably, 3.4-3.5.
- gluconic acid For 10 percent calcium gluconate solution, about 56 mg./ml. of gluconic acid is required to obtain this pH.
- the resulting solution is then adjusted tothe total volume required by the addition, if necessary, of up to about 10 or 20 percent of its volume of water for injec ⁇ tion.
- the solution is then filtered through a 0.2 micron filter to prevent nucleation by crystallites or contam- inants in the solution.
- the solution is then filled into 50 ml. glass ampules, stoppered with a conventional ampule closure, and autoclaved for 35 minutes.
- ampules may be trans ⁇ ferred by injection needle using normal aseptic technique into a flexible, collapsible container of amino acid injection solution containing dissolved phosphate and other electrolytes, the amino acid injection solution typically having a pH of 6 to 8, without formation of any precipitate.
- a typical pH value for such amino acid injection solutions is 7.5.
- a typical glass ampule 10 containing a solution of this invention is shown.
- the ampule is closed with a conventional latex needle-piercable dia ⁇ phragm 12, and is autoclaved before use.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Treating Waste Gases (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71643285A | 1985-03-27 | 1985-03-27 | |
US716432 | 1985-03-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0215925A1 EP0215925A1 (en) | 1987-04-01 |
EP0215925A4 true EP0215925A4 (en) | 1987-10-26 |
Family
ID=24877971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860902230 Withdrawn EP0215925A4 (en) | 1985-03-27 | 1986-03-24 | Supplemental calcium addition unit. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0215925A4 (en) |
JP (1) | JPS62502261A (en) |
AU (1) | AU5628386A (en) |
WO (1) | WO1986005688A1 (en) |
ZA (1) | ZA862326B (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3621094A (en) * | 1968-04-05 | 1971-11-16 | Smith Kline French Lab | Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts |
CA1017249A (en) * | 1973-12-19 | 1977-09-13 | Chemo Drug Company | Injectable electrolyte solutions |
JPS5632411A (en) * | 1979-08-27 | 1981-04-01 | Tomita Seiyaku Kk | Preparation of perfusion liquid for artificial kidney dialysis |
US4308255A (en) * | 1980-03-24 | 1981-12-29 | Haemophor Corporation | Balanced oncotic pressure fluid |
US4410321A (en) * | 1982-04-06 | 1983-10-18 | Baxter Travenol Laboratories, Inc. | Closed drug delivery system |
-
1986
- 1986-03-24 WO PCT/US1986/000593 patent/WO1986005688A1/en not_active Application Discontinuation
- 1986-03-24 JP JP61501901A patent/JPS62502261A/en active Pending
- 1986-03-24 AU AU56283/86A patent/AU5628386A/en not_active Abandoned
- 1986-03-24 EP EP19860902230 patent/EP0215925A4/en not_active Withdrawn
- 1986-03-27 ZA ZA862326A patent/ZA862326B/en unknown
Non-Patent Citations (2)
Title |
---|
No relevant documents have been disclosed. * |
See also references of WO8605688A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1986005688A1 (en) | 1986-10-09 |
JPS62502261A (en) | 1987-09-03 |
AU5628386A (en) | 1986-10-23 |
ZA862326B (en) | 1986-11-26 |
EP0215925A1 (en) | 1987-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3980200B2 (en) | Peritoneal dialysis solution | |
NO161204B (en) | PROCEDURE FOR PREPARING AN INSULIN SOLUTION. | |
CA1170990A (en) | Stabilized insulin preparations and method for their production | |
CN106822175A (en) | A kind of sodium acid carbonate ringer's injection and preparation method thereof | |
DE60215129T2 (en) | ESMOLOL-CONTAINING PREPARATIONS | |
Lenz et al. | Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing Aminosyn-PF or TrophAmine | |
Watson | Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions | |
Mackay et al. | The solubility of calcium and phosphate in two specialty amino acid solutions | |
WO1986005688A1 (en) | Supplemental calcium addition unit | |
Soges Bettner et al. | Effects of pH, temperature, concentration, and time on particle counts in lipid‐containing total parenteral nutrition admixtures | |
US5650421A (en) | Premixed famotidine formulation | |
JPH03135918A (en) | Immune-activating agent | |
SE463804B (en) | AN APPLICABLE PHARMACEUTICAL COMPOSITION OF WINE ADDITIONAL SALTS | |
NO864743L (en) | SUPPLEMENTARY CALCIUM ADDITIVE UNIT. | |
JPH06135852A (en) | Urinastatin injection | |
JP4575659B2 (en) | Injection | |
JPH0469341A (en) | Sugar electrolytic solution for tpn | |
US6187818B1 (en) | Prostaglandins formulation and process | |
JP5623682B2 (en) | Trace element formulation | |
CN102949413B (en) | Method for preparing invert sugar and electrolytes injection | |
SU1395327A1 (en) | Infusion solution for correcting metabolic alkalosis "sorbamin" | |
CN100333728C (en) | Compound electrolytic fructose injection | |
Filler | Total parenteral feeding of infants | |
Kirkpatrick et al. | Effect of retrograde aminophylline administration on calcium and phosphate solubility in neonatal total parenteral nutrient solutions | |
JPH0283327A (en) | Glucose electrolyte preparation for high calorie infusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19861125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): BE CH DE FR GB IT LI NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19871026 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19891003 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GUPTA, SHANKER, L. Inventor name: STONE, ALBERT Inventor name: MILLER, JOHN, C. Inventor name: DAWE, ROBIN |